Riskpilot← Back to searchSign inGet full accessBIONOR IMMUNO AS
ASActiveOrg 982248108Karenslyst Allé 6, 0278 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20000 employees
Revenue 2024
NOK 0
EBITDA margin
—
+80% vs 2023
Equity ratio
-12415.0%
Financial strength
Net profit 2024
NOK -167K
+64% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -93K | +80% |
| Net profit | NOK -167K | +64% |
| Total assets | NOK 138K | -9% |
| Equity | NOK -17,1M | -1% |
| Employees | 0 | — |
Legal name
BIONOR IMMUNO AS
Org number
982248108
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. august 2000
Share capital
NOK 983 784
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap eller av ett styremedlem og daglig leder i fellesskap.
Company purpose
Handel, rådgivning, produksjon, bioteknologisk forskning, utvikling og kommersialsiering, eie og forvalte aksjer og andre verdipapirer, delta i andre foretak og alt som har forbindelse med dette.
Address
Karenslyst Allé 6, 0278 Oslo
Phone
+4723010960
Email
uh@bionorpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192 | 1 310 | 0 | 0 | 259 | 14 459 | 7 254 | 40 | 0 | 419 | 0 | 64 | 0 | 0 | 0 |
| Staff expenses | −6 963 | −14 314 | −0 | −0 | −1 | −0 | −0 | −4 940 | −1 213 | −149 | −791 | −15 | −0 | −6 | 270 |
| EBITDA | −17 802 | −31 757 | 0 | 0 | −44 053 | −37 946 | −27 127 | −11 307 | −6 827 | −8 407 | −4 794 | −2 590 | −5 131 | −460 | −93 |
| Depreciation & amort. | −116 | −2 643 | −0 | −0 | −2 259 | −2 255 | −9 473 | −41 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −17 918 | −34 400 | 0 | 0 | −46 312 | −40 201 | −36 600 | −11 348 | −6 827 | −8 407 | −4 794 | −2 590 | −5 131 | −460 | −93 |
| Net financials | −3 531 | −9 588 | 0 | 0 | −10 373 | −5 281 | −5 736 | −749 | 6 | −112 | −197 | −15 | 0 | 0 | −75 |
| Profit before tax | −21 449 | −43 988 | 0 | 0 | −56 685 | −45 482 | −42 336 | −12 097 | −6 821 | −8 519 | −4 990 | −2 605 | −5 131 | −460 | −167 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −21 449 | −43 988 | 0 | 0 | −56 685 | −45 482 | −42 336 | −12 097 | −6 821 | −8 519 | −4 990 | −2 605 | −5 131 | −460 | −167 |
| Item | 2008 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 132 053 | 29 933 | — | — | 39 751 | 37 868 | 96 308 | 901 | 2 108 | 2 888 | 451 | 292 | 371 | 151 | 138 |
| Equity | 62 208 | −87 660 | — | — | −25 965 | −71 447 | 75 794 | −824 | −2 145 | −3 764 | −8 755 | −11 360 | −16 491 | −16 951 | −17 119 |
| Long-term debt | 51 536 | 2 865 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 059 | 5 059 | 5 059 | 0 | 79 | 0 |
| Short-term debt | 18 308 | 114 728 | 0 | 0 | 65 716 | 109 315 | 20 514 | 1 725 | 4 253 | 1 593 | 4 147 | 6 593 | 16 862 | 17 024 | 17 257 |
| Total debt | 69 845 | 117 593 | 0 | 0 | 65 716 | 109 315 | 20 514 | 1 725 | 4 253 | 6 653 | 9 206 | 11 653 | 16 862 | 17 103 | 17 257 |
EBITDA margin
-9269500.0%
This company
15.8%
Market median
-58667822% vs market
20082024
Equity ratio
-12415.0%
This company
38.2%
Market median
-32600% vs market
20082024
Return on equity
-16742000.0%
This company
18.4%
Market median
-90989230% vs market
20082024
Net profit margin
-16742000.0%
This company
8.1%
Market median
-206691458% vs market
20082024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082024
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Bionor Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bionor Holding As
BIONOR IMMUNO AS Board members of BIONOR IMMUNO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag Arne Wivelstad | Board of Directors | 0 companies |
| Aslak Aslaksen | Board of Directors | 0 companies |
| Birger Sørensen | Chairman | 0 companies |